[ad_1]
© Reuters. FILE PHOTO: The company’s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS / Arnd Wiegmann / File Photo
ZURICH (Reuters) – Novartis said it resumed the production and delivery of radioligand therapy medicines after fixing the issues that had led to a temporary suspension of production last month.
“The company has remediated the issues that led to the temporary, voluntary suspension of production in May,” the Swiss drugmaker said in a statement, adding these issues did not affect patient safety.
[ad_2]
Source link
